Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 563-564

  Bishop, Michael R ^a   Alyea, Edwin P ^a,b   Cairo, Mitchell S ^a,c   Falkenburg, J H Frederik ^a,d   June, Carl H ^a,e   Kröger, Nicolaus ^a,f   Little, Richard F ^a   Miller, Jeffrey S ^a,g   Pavletic, Steven Z ^a   Porter, David ^a,e   Riddell, Stanley R ^a,h   van Besien, Koen ^a,i   Wayne, Alan S ^a   Weisdorf, Daniel J ^a,g   Wu, Roy ^a   Giralt, Sergio ^a,j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF MINNESOTA   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; EDITORIAL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; REDUCED INTENSITY CONDITIONING; RISK FACTOR; TUMOR MICROENVIRONMENT;

CONGRESSES AS TOPIC; GROUP PROCESSES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 77951588418     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.025     Document Type: Editorial

References (16)

1. Gratwohl A., Brand R., Frassoni F., et al. Acute and chronic leukemia working parties; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005, 36:757-769.
2. Kolb H.J., Mittermüller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
3. Crawley C., Iacobelli S., Björkstrand B., Apperley J.F., Niederwieser D., Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007, 109:3588-3594.
4. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
5. Ringdén O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
6. Gale R.P. Approaches to leukemic relapse following bone marrow transplantation. Transplant Proc 1978, 10:167-171.
7. Frassoni F., Barrett A.J., Grañena A., et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988, 70:317-320.
8. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
9. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
10. Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671-3680.
11. Shimoni A., Gajewski J.A., Donato M., et al. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2001, 7:568-575.
12. Porter D.L., Levine B.L., Bunin N., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006, 107:1325-1331.
13. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
14. Welniak L.A., Blazar B.R., Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
15. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
16. Fefer A., Cheever M.A., Greenberg P.D. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986, 76:1269-1273.